Therapeutics and Clinical Risk Management

Dove Medical Press is pleased to invite you to submit your research to an upcoming Thematic Series on "Asthma”, in Therapeutics and Clinical Risk Management, edited by our journal Editor in Chief Professor Garry Walsh.

Upon submission, please use the promo code DKPCL for 20% off the advertised article processing charge and indicate that your manuscript will be considered for the Thematic Series of “Asthma”. The deadline for manuscripts is the 31 July 2023.
For any inquiries, please email Jermaine Wilcock, Commissioning Editor at [email protected]

About the Thematic Series

Asthma remains a major cause of ill-health worldwide that presents as a heterogeneous, chronic inflammatory airways disorder characterized by complex and diverse inflammatory processes including goblet cell hyperplasia, airway smooth muscle hypertrophy and sub-epithelial fibrosis that give rise to airway hyperresponsiveness (AHR) and reversible airflow limitation. Asthma can be divided into ‘asthma phenotypes’ that take demographic, clinical and/or pathophysiological characteristics into account.

A further refinement involves division into disease entities termed ‘asthma endotypes’ based on specific pathophysiological mechanisms. For example, T helper 2 (TH2)-high asthma is seen in around 50% of patients who typically have eosinophilic inflammation mediated by cytokines including IL-4, IL-5 and IL-13. Elevated levels of immunoglobulin E (IgE) may also be present, while both Th2 and non-Th2 mechanisms contribute to asthma pathogenesis. Furthermore, respiratory viral infection is known to be a common risk factor for asthma exacerbations, although the underlying mechanisms require further investigation.

Most asthmatic patients achieve satisfactory symptom control using inhaled glucocorticosteroids and bronchodilators such as β2-adrenergic agonists, with the addition of oral leukotriene inhibitors if required. However, severe disease is seen in the region of 5% of asthmatic subjects who do not achieve satisfactory asthma control despite adherence to high dose inhaled or systemic glucocorticoid therapies giving rise to recurrent exacerbations and persistent symptoms together with significant morbidity, quality of life issues with attendant health cost implications.

This Special Thematic Issue of Therapeutics and Clinical Risk Management will address key aspects of the pathogenesis of asthma that informs diagnosis and treatment together with the development of more effective novel therapy for this important and common condition. The journal is seeking original submissions and review articles on the following topics related to:
• Current asthma therapy
• Severe asthma
• Paediatric asthma
• Co-morbidities; rhinitis; obesity, COPD
• COVID-19
• Viral infection
• The role of pro-inflammatory cells including T cells; mast cells; eosinophils; neutrophils; epithelial cells and smooth muscle cells
• Biomarkers
• Monoclonal antibody based biologic therapy (IgE; IL4/13; IL-5)

Submit your manuscript

https://www.dovepress.com/submit_step_1.php

View all papers in this thematic series